Neoprobe to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
10 November 2011 - 6:15PM
Business Wire
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer
of innovative oncology surgical and diagnostic products, today
announced that Dr. Mark Pykett, Neoprobe’s President and Chief
Executive Officer, will deliver a presentation to institutional
investors at 2:00 PM ET, Tuesday, November 15, 2011 at the Lazard
Capital Markets Healthcare Conference, taking place at The Pierre
Hotel, New York.
Investors and the public are invited to listen to a live webcast
of Dr. Pykett’s presentation at http://wsw.com/webcast/lz11/neop/.
An archived version of the presentation will be available for 30
days following the presentation.
About Neoprobe
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company
focused on enhancing oncology patient care and improving patient
benefit through radiopharmaceutical product development. Neoprobe
is actively developing two radiopharmaceutical agent platforms –
Lymphoseek® and RIGScanTM CR – to help surgeons better identify and
treat certain types of cancer. Neoprobe’s subsidiary, Cira
Biosciences, Inc., is also exploring development of a
patient-specific cellular therapy technology platform called ACT.
Neoprobe’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and
advancing the Company’s pipeline program through continued
investment and selective acquisitions. For more information, please
visit www.neoprobe.com.
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Neoprobe Corp. Common Stock (Amerikanische Börse): 0 Nachrichtenartikel
Weitere Neoprobe Corporation News-Artikel